0.46
-0.0046(-1.00%)
Currency In USD
| Previous Close | 0.46 |
| Open | 0.47 |
| Day High | 0.49 |
| Day Low | 0.45 |
| 52-Week High | 8.78 |
| 52-Week Low | 0.41 |
| Volume | 263,911 |
| Average Volume | 464,954 |
| Market Cap | 24.32M |
| PE | -0.19 |
| EPS | -2.45 |
| Moving Average 50 Days | 0.51 |
| Moving Average 200 Days | 1.18 |
| Change | -0 |
If you invested $1000 in ALX Oncology Holdings Inc. (ALXO) since IPO date, it would be worth $15.17 as of June 25, 2025 at a share price of $0.455. Whereas If you bought $1000 worth of ALX Oncology Holdings Inc. (ALXO) shares 3 years ago, it would be worth $55.64 as of June 25, 2025 at a share price of $0.455.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
ALX Oncology to Present at the Jefferies 2025 Global Healthcare Conference
GlobeNewswire Inc.
May 30, 2025 12:00 PM GMT
SOUTH SAN FRANCISCO, Calif., May 30, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and
ALX Oncology Highlights Differentiated Design, Preclinical Data and Development Plans for EGFR-Targeted ADC, ALX2004, in R&D Webcast Event
GlobeNewswire Inc.
May 20, 2025 12:00 PM GMT
- A potential best- and first-in-class antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors, ALX2004 is uniquely designed with every component optimized to maximize the therapeutic window by reducing toxicity - Following re
ALX Oncology to Host R&D Webcast Event Highlighting its Novel EGFR Targeting Antibody-Drug Conjugate, ALX2004, on May 20, 2025
GlobeNewswire Inc.
May 13, 2025 12:00 PM GMT
SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and